The article states plainly that this combination is not standard practice for weight management and falls outside standard-of-care protocols
Lingvay I, Cheng AY, Levine JA, Gomez-Valderas E, Allen SE, Ranta K, Torcello-Gomez A, Thieu VT (2023) Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: a post hoc analysis of the SURPASS-1 to -5 studies
DSIP has been studied in small pre-clinical trials where it demonstrated the ability to reduce the perception of pain while simultaneously supporting improvements in mood
(Accessed 2025) for general background and side effect incidence from Phase 3 trials
To perform these functions, it must be present in a so-called reduced form
However, clearly a larger patient cohort would be necessary to ultimately rule out possible correlations